BioNTech SE
BioNTech SE (BNTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BNTX · as of Sep 30, 2025
Ownership Breakdown
289
Institutional Holders
▲ 2 vs Q2
$4.98B
Total Inst. Value
▼ $745.78M vs Q2
252.88M
Shares Outstanding
freeFloat 99.63%
50.53M
13F Shares Held
▼ 3.24M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BNTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAILLIE GIFFORD & CO biological products, (no diagnostic substances) | 7.88M | 3.26% | 3.26% | $777.06B | Oct 31, 2025 | ▼ 159.5K |
FMR LLC biological products, (no diagnostic substances) | 5.45M | 2.26% | 2.26% | $537.82B | Nov 13, 2025 | ▼ 2.71M |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 4.83M | 2.00% | 2.00% | $476.69B | Nov 14, 2025 | ▲ 1.24M |
FLOSSBACH VON STORCH AG biological products, (no diagnostic substances) | 4.23M | 1.75% | 1.75% | $417.17B | Nov 3, 2025 | ▼ 65 |
PRIMECAP MANAGEMENT CO/CA/ biological products, (no diagnostic substances) | 3.87M | 1.60% | 1.60% | $381.73B | Nov 12, 2025 | ▼ 130.7K |
DODGE & COX biological products, (no diagnostic substances) | 3.65M | 1.51% | 1.51% | $359.68B | Nov 13, 2025 | ▲ 2.77M |
PFIZER INC biological products, (no diagnostic substances) | 1.66M | 68.63% | 68.63% | $163.55B | Nov 13, 2025 | ▼ 2.00M |
TEMASEK HOLDINGS (PRIVATE) LTD biological products, (no diagnostic substances) | 1.51M | 62.33% | 62.33% | $148.52B | Nov 14, 2025 | — held |
CAPITAL INTERNATIONAL INVESTORS biological products, (no diagnostic substances) | 1.14M | 46.98% | 46.98% | $111.94B | Nov 13, 2025 | ▲ 1.6K |
BNP PARIBAS ARBITRAGE, SNC biological products, (no diagnostic substances) | 1.10M | 45.66% | 45.66% | $108.81B | Nov 13, 2025 | ▼ 172.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+6.40M shares0
New Positions
first time holders22
Decreased
−7.61M shares0
Sold Out
fully exitedNet shares change (top 50)
1.21M
+6.40M / −7.61M
Net new holders
+2
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BNTX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Zapata Gomez Ramon Chief Financial Officer | May 12, 2026 | Award | 18,879 | — | — | 18.9K | Form 4 ↗ |
Zapata Gomez Ramon Chief Financial Officer | May 12, 2026 | Award | 15,103 | — | — | 15.1K | Form 4 ↗ |
Ryan James Timothy Patrick See remarks. | May 12, 2026 | Award | 12,586 | — | — | 12.6K | Form 4 ↗ |
Ryan James Timothy Patrick See remarks. | May 12, 2026 | Award | 10,069 | — | — | 10.1K | Form 4 ↗ |
Poetting Sierk Chief Operating Officer | May 12, 2026 | Award | 12,586 | — | — | 12.6K | Form 4 ↗ |
Poetting Sierk Chief Operating Officer | May 12, 2026 | Award | 10,069 | — | — | 10.1K | Form 4 ↗ |
Jimenez Kylie Chief People Officer | May 12, 2026 | Award | 10,488 | — | — | 10.5K | Form 4 ↗ |
Jimenez Kylie Chief People Officer | May 12, 2026 | Award | 8,391 | — | — | 8.4K | Form 4 ↗ |
Hanekamp Annemarie Chief Commercial Officer | May 12, 2026 | Award | 12,586 | — | — | 12.6K | Form 4 ↗ |
Hanekamp Annemarie Chief Commercial Officer | May 12, 2026 | Award | 10,069 | — | — | 10.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BioNTech SE (BNTX) is primarily owned by institutional investors, who hold approximately 20.0% of total shares outstanding. Company insiders own approximately 0.37%, while retail and public investors account for the remaining 79.65%.
The largest institutional shareholder of BioNTech SE is BAILLIE GIFFORD & CO, holding approximately 7.88 million shares — equal to 3.26% of outstanding shares — as of September 30, 2025.
A total of 289 institutional investors currently hold BNTX stock, with a combined institutional value of approximately $4.98 billion as of the most recent 13F filing period.
Frequently asked questions
BNTX ownershipBioNTech SE (BNTX) is primarily owned by institutional investors, who hold approximately 20.0% of shares. The largest shareholder is BAILLIE GIFFORD & CO with a 3.26% stake. Company insiders hold 0.37%. Data sourced from SEC Form 13F as of September 30, 2025.